Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. Foresee Pharmaceuticals Co., Ltd. was incorporated in 2013 and is based in Taipei, Taiwan.
Metrics to compare | 6576 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6576PeersSector | |
---|---|---|---|---|
P/E Ratio | −12.7x | −63.7x | −0.6x | |
PEG Ratio | −1.75 | −1.07 | 0.00 | |
Price/Book | 16.8x | 2.8x | 2.6x | |
Price / LTM Sales | 34.1x | 6.6x | 3.1x | |
Upside (Analyst Target) | 65.8% | 0.0% | 55.1% | |
Fair Value Upside | Unlock | −10.6% | 9.2% | Unlock |